ArriVent BioPharma/$AVBP
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About ArriVent BioPharma
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
Ticker
$AVBP
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
52
ISIN
US04272N1028
Website
AVBP Metrics
BasicAdvanced
$722M
-
-$3.78
-
-
Price and volume
Market cap
$722M
52-week high
$34.51
52-week low
$15.47
Average daily volume
466K
Financial strength
Current ratio
14.343
Quick ratio
13.633
Total debt to equity
0.068
Profitability
Management effectiveness
Return on assets (TTM)
-23.10%
Return on equity (TTM)
-49.00%
Valuation
Price to book
3.55
Price to tangible book (TTM)
3.55
Price to free cash flow (TTM)
-5.943
Free cash flow yield (TTM)
-16.83%
Free cash flow per share (TTM)
-355.06%
Growth
Earnings per share change (TTM)
-59.00%
What the Analysts think about AVBP
Analyst ratings (Buy, Hold, Sell) for ArriVent BioPharma stock.
AVBP Financial Performance
Revenues and expenses
AVBP Earnings Performance
Company profitability
AVBP News
AllArticlesVideos
Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Benzinga·2 days ago
ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewsWire·2 days ago
ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewsWire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ArriVent BioPharma stock?
ArriVent BioPharma (AVBP) has a market cap of $722M as of July 04, 2025.
What is the P/E ratio for ArriVent BioPharma stock?
The price to earnings (P/E) ratio for ArriVent BioPharma (AVBP) stock is 0 as of July 04, 2025.
Does ArriVent BioPharma stock pay dividends?
No, ArriVent BioPharma (AVBP) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next ArriVent BioPharma dividend payment date?
ArriVent BioPharma (AVBP) stock does not pay dividends to its shareholders.
What is the beta indicator for ArriVent BioPharma?
ArriVent BioPharma (AVBP) does not currently have a Beta indicator.